On December 19, 2019, Xu Songsan, Chairman of the company, and Park, Chung-Gwon, General Manager of South Korea's GCEM, signed a project design agreement at the headquarters of South Korea's Green Cross Group. GCEM will undertake the design work for the second phase of NORTHLAND's industrialization base—the "Biopharmaceutical Production Base."

　　The primary function of the “Biopharmaceutical Production Base” is to undertake the industrial-scale production of innovative drugs developed by the company. The project is planned to cover a construction area of 38,000 square meters and is expected to be completed in 2022. The construction scope includes a bulk drug substance production workshop, a formulation production workshop, a CMO production workshop, a pilot-scale workshop, a research and development center, and a raw and auxiliary material warehouse. The facility will be capable of producing both microorganism-expressed drugs and animal-cell-expressed drugs. While meeting the company’s own R&D drug production and supply needs, the base will also provide CDMO services to external clients, fully leveraging its production capacity advantages to support the development of biomedical enterprises in the capital city. This project was included in the Beijing Municipal Bureau of Economy and Information Technology’s Major High-Precision and Advanced Projects Database for 2019.

　　Since the two parties signed the letter of intent for cooperation on October 18, project personnel have engaged in close communication over the past two months, repeatedly discussing the project’s design details, requirements, and underlying concepts, and ultimately reached a consensus. Xu Songshan, Chairman of the company, stated: “Our company’s biopharmaceuticals, which are progressing most rapidly, have already entered Phase III clinical trials and are expected to obtain regulatory approval within the next two to three years. Now that we’re launching the conceptual design phase, the timing couldn’t be better. GCEM is a renowned design firm in the industry with extensive experience in biopharmaceutical project design. In recent years, GCEM has undertaken the design and construction of numerous biopharmaceutical facilities. By choosing to collaborate with GCEM this time, we hope to bring cutting-edge international concepts from global biopharmaceutical companies into China and build a first-class, intelligent biopharmaceutical production base integrating R&D, manufacturing, and warehousing.”

　　This project will be designed strictly in accordance with international pharmaceutical manufacturing quality standards. By introducing automated, continuous, and intelligent production equipment as well as a full-process data interaction system, we will achieve real-time monitoring and control, thereby reducing human errors and contamination during the production process and ensuring the highest quality of pharmaceutical products. While complying with China’s GMP standards, this project will also meet the GMP standards of the European Union and the United States.

　　Founded in 2001, South Korea’s GCEM Company specializes in project design, project consulting, construction management, and validation consulting services, and boasts extensive experience in project design. Since its establishment, the company has completed the design work for over 60 projects, including the design of 30 biopharmaceutical projects, six of which have successfully obtained U.S. FDA and EU GMP certifications.